Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers.
BACKGROUND
Recent studies examining the moderating effects of polymorphic variation in opioid receptor genes have yielded conflicting results. We examined opioid receptor gene polymorphisms as moderators of the therapeutic effects of the opioid antagonist nalmefene.


METHODS
Participants (n = 272) were subjects who consented to the pharmacogenetic analysis of a multi-site, randomized, placebo-controlled trial of targeted nalmefene for the reduction of heavy drinking. We genotyped two single nucleotide polymorphisms (SNPs) in OPRM1 (including A118G, a commonly studied SNP that encodes an Asn40Asp amino acid substitution), two SNPs in OPRD1, and one SNP in OPRK1, which encode the mu-, delta-, and kappa-opioid receptors, respectively. Regression analysis served to examine the moderating effects of these SNPs on medication response.


RESULTS
As previously described by Karhuvaara et al. (2007), nalmefene significantly reduced the number of heavy drinking and very heavy drinking days per week, compared with placebo. There were no main or moderating effects of the genotypes examined on these outcomes.


CONCLUSIONS
Our finding that the therapeutic effects of targeted nalmefene were not moderated by polymorphic variation in opioid receptor genes is consistent with two recent reports showing that variation in opioid receptor genes does not moderate the response to naltrexone. However, these findings contrast with those from two other studies, in which the Asn40Asp polymorphism in OPRM1 moderated the naltrexone treatment response. Additional research is needed to clarify the role of variation in opioid receptor genes on the response to opioid antagonist treatment of alcoholism.
Alcohol Research Center, University of Connecticut School of Medicine, Farmington, Connecticut 06030-2103, USA.
Albert J
AJ
Arias
Stephen
S
Armeli
Joel
J
Gelernter
Jonathan
J
Covault
Antero
A
Kallio
Sakari
S
Karhuvaara
Tiina
T
Koivisto
Rauno
R
Mäkelä
Henry R
HR
Kranzler
D000328:Adult; D019973:Alcohol-Related Disorders / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide; D016032:Randomized Controlled Trials as Topic; D011957:Receptors, Opioid / Q000235:genetics*; D016896:Treatment Outcome
D009292:Narcotic Antagonists; D011957:Receptors, Opioid; D009271:Naltrexone; C038981:nalmefene